Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How did that work out for you?
Dew, Thanks, my friends are not in the US but I will certainly follow up on the link you provided.
I am wondering in you have read the book on what happened with DNDN:
https://www.amazon.com/Dendreon-Effect-men-Manipulate-High-tech/dp/1563431416
Not sure what I think though I do remember that at the time thinling that the system had been somewhat compromised to the detriment of cancer patients.
Hi. There are several approved drugs approved for prostate cancer that were not available when Provenge was launched about ten years ago. Before making a treatment decision, any cancer patient should consider getting a genetic screen such as FoundationOne CDx (https://www.foundationmedicine.com/genomic-testing/foundation-one-cdx ), which is offered by Foundation Medicine, a subsidiary of Roche.
Good luck. Regards, Dew
I an doing some research into Dendrion for two reasons
1. Cloee friends have Prostate Cancer
2 Dendreon effect has been brought up
I remember you were involved in posting on the Advisory meeting and other DNDN events. We both posted on GENR board.
Wonder if you are still around and have any comments in hindsight.
No volume, no revenue, no information, debt issues everyone has moved on.
DNDN from LONG AGO... since someone posted it on another board
Posted on 18 June 2009
https://www.deepcapture.com/2009/06/michael-milken-60000-deaths-and-the-story-of-dendreon-chapter-1-of-15/
Don't think so...
one of the worst collapses in stock market history,4 years of misery
It is still $45 if you take in account all the outstanding shares. If the market cap goes down by half while at the same time share value has doubled from .01 to .02 then what has taken place for this to happen.
You have a +100% move upwards and a 50% move downwards your aand the last known outstanding share count was 60 million.
The spread is a 150% times 60 million equals 180 million shares from 60 million she is not rocket science how it is done my friends. Remember you can't sell nothing and what you do have you can ask the world should someone agree to pay the price for it.
Now take the asset value and divide that by the new outstanding shares and is not the value reflective of the price when taking in the debt owed to previous share holders.
Everyone pays the same price if you don't trade while others pay less or more in some cases who do trade the stock.
Link to bankruptcy information:
https://cases.primeclerk.com/dendreon/
The final nail, from today at Fidelity:
06/12/2015 EXPIRED DENDREON CORP COM **EXPIRED POSITION**
24823Q107 DENDREON CORP COM **EXPIRED POSITION**
I'm waiting for it to reach par status before buying to avoid dilution.
Chapter 11 is money owed to owners where as chapter 7 is to creditors like banks ect. The collateral is in threat not that investors have to come up with more capital but it does help some when they do sell them at par to raise more capital.
Waiting for the dust to settle....all Q can't be all winners that's why the Q stands for Questionable ;/ maybe a small light at end of the tunnel?
Bankruptcy Plan Effective/Shares Cancelled 06/11/2015
http://otce.finra.org/DailyList
we may see it at .45 very soon!
This was once 45.00 a share lmao at this disaster
Going long and strong.....high risk high reward....that's the name of this game ;)
DNDNQ to open over a dime on Monday!
Going long and strong last shake out for weak hands...we will see on the 10th the outcome.....high risk high reward....the name of this game ;)
Going long and strong unsecured holders will receive lollipops :)~~~~~
docket 714 is interesting, what do you think about it?
Wake wake it's almost June or maybe July will see if we get our lollipop ;) holding long and strong
Looks good on paper. Moved on guys see you at the next play.
They don,t tell you stuff like that. If you should ask they will deny your conspiracy but again it is true that if you buy land dig a whole and add cement you have devalued that land until the completion of the final product and should that product be ten years older down the block and be of the same DNA it will be priced at the last sale on the block.
Now if it is full of special equipment designed for a particular process well then it is priced at what it produces in profits.
So as you see it can all be manipulated and what one has to do is make the ones in charge accountable.
Anyhow the long and short is I don't know so I won't hang on to them cause I don't know and what I have is only speculation on my part and my buddies who I share the alias with.
Hmmmmmmm let me know when you find out :)
Patient wake me up in June :)
Still holding no bids and no asks? She is in limbo.
http://www.deonsupply.com/
Fighting cancer by taking the recycled oil process out of the equation.
http://en.wikipedia.org/wiki/Automotive_oil_recycling
Did you now that the industry encourages you to change your oil more often due too the refining process along with always changing your oil filter on a regular bases to cut down refining cost.
Apr 13, 2015 13:54:00 (ET)
By Joseph Checkler
Drug maker Dendreon Corp. (DNDNQ) is offering details of how it will distribute to creditors the money from its sale to Valeant Pharmaceuticals International Inc. (VRX, VRX.T).
In a Friday Filing with U.S. Bankruptcy Court in Wilmington, Del., Dendreon said the holders of its key unsecured notes will get between 72 cents and 75 cents on the dollar, thanks to the $495 million sale to Valeant.
Those creditors, the largest group owed money in Dendreon's bankruptcy case, would have gotten much less earlier in the case, but the Valeant offer kept getting higher. At one point, Valeant was only going to buy Dendreon's flagship prostate cancer drug, Provenge, but eventually it bought all the company's assets.
The Friday filing was an updated version of Dendreon's so-called disclosure statement, a plain-language version of a company's restructuring plan on which creditors must vote. A prior version of the document hadn't placed a printed figure on how much the creditors would get. Other unsecured creditors will also get between 72 cents and 75 cents on the dollar.
Originally, Valeant offered $296 million for Dendreon assets, including Provenge. That offer was increased to $400 million when Valeant was approved to serve as the stalking horse, or lead bidder, at a bankruptcy auction that was ultimately canceled when no rival bidders emerged to challenge Valeant. It eventually went up to $495 million.
The deal is Valeant's first big move since its failed hostile takeover of Botox maker Allergan Inc. (AGN). Actavis PLC ended up buying Allergan in November for $66 billion. After losing out on Allergan, Valeant indicated it would focus on expanding its own business. But Dendreon became too tempting a target.
Once a darling of hedge funds betting both on and against Provenge's prospects, Dendreon's market capitalization once topped $7.5 billion after Food & Drug Administration approval of the drug.
But at an average of $93,000 for a course of treatment that improved median survival by just over four months, Provenge wasn't adopted readily by doctors. The company's stock started to plummet in August 2011 after it offered lower revenue guidance, prompting an investor lawsuit, which was eventually settled, and a stock freefall.
That led to a Chapter 11 filing, in November 2014.
Provenge had about $300 million in 2014 revenue. Valeant hired Dendreon's employees and agreed to take over the supply contracts for the acquired business, a component of the purchase that stabilizes Dendreon's operations.
(Dow Jones Daily Bankruptcy Review covers news about distressed companies and those under bankruptcy protection. Go to http://dbr.dowjones.com)
Write to Joseph Checkler at joseph.checkler@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
April 13, 2015 13:54 ET (17:54 GMT)
Taking her to the bank today.
Looks like those bag holders will be receiving around .72c to .75c good thing I'm long and strong on this I'll be smiling all the way to the bank :)~~~ more lollipops for me!!!!
Its trading over $.04 down to $.03 how much do you need to be saved. They are doing every thing they can for both the share holders and debt holders by creating depreciated assets for one group and liquidity for another group but it is up too share holders to take advantage of what has been given them.
Debt holders do not get that chance but do get the chance of collecting on the depreciated assets once things are resolved.
why didn't nol's save the shareholders?
Followers
|
223
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12660
|
Created
|
07/17/05
|
Type
|
Free
|
Moderators |
Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization, and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering, and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 and by the European Medicines Agency in 2013. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and has manufacturing facilities in Georgia and California.
PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to take the body’s own immune cells and reprogram them to attack advanced prostate cancer.
PROVENGE full Prescribing Information
For more information about PROVENGE, please visit www.PROVENGE.com.
US Health Care Professionals can visit the Medical Affairs Web site to submit a request online.
http://www.dendreon.com/products/provenge/manufacturing/
http://www.dendreon.com/products/provenge/scientific_publications/
The Patient Resources section includes information about patient access, clinical trials and patient information.
For Questions about PROVENGE® (sipuleucel-T), contact Dendreon ON Call:
Phone: 877-336-3736
Fax: 877-556-3737
http://www.dendreon.com/patient_resources/patient_access/
Dendreon has several ongoing clinical trials, including:
Sipuleucel-T Clinical Trials
P10-1
P10-2
P10-3 (called PROCEED)
P11-1
P11-3
P11-4 (PRIME)
P12-1
P12-2
Additional ACI Product Candidate Clinical Trials
N10-1 (called Neu-ACT)
To find out more about cancer and specifically prostate cancer, we have provided a list of patient-focused cancer organizations.
PipelineInvestigational product candidates in the Dendreon pipeline include:
Stock Quote (NASDAQ: DNDN) Price: 2.04 Change: + 0.03 Volume: 1,783,600 4:00 PM ET on Jun 13, 2014 Delayed at least 20 minutes. Provided by eSignal. |
Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |